Literature review
Scienceevidence in cancer
Define the field
We started from the scientific literature, building a list of cytokines with any evidence of a role in cancer development and progression.
Case Study · Technology Assessment
Which cytokines hold real promise for cancer therapy?
A leading biotechnology company wanted to grow its cancer portfolio beyond classical treatments and needed to know where cytokine therapies stood. We reviewed the science and the competition and helped the client see where to look next.
The Client
The client is a leading biotechnology company planning to grow its cancer treatment portfolio beyond classical approaches. It engaged Prescouter to map the therapeutic opportunities for cytokines and cytokine inhibitors in anticancer therapy.
The Challenge
Explain the biology.
Track what companies are building.
Prescouter was asked to give a clear overview of the biology of the most relevant cytokines and to sum up the strategies companies are using to bring cytokines into cancer therapy.
-
The science
Evidence in cancer
Which cytokines have evidence supporting a role in cancer development and progression.
-
The drug case
Druggability and clinical use
How readily each cytokine can be targeted, and how useful it could be in the clinic.
-
The field
Key player activity
What leading companies are doing to develop new cytokine-based therapeutics.
Our Approach
Reviewing the science, then ranking the best candidates.
Shortlisting
Rankedtop cytokines profiled
Score the candidates
The top cytokines were shortlisted and profiled on the strength of the scientific evidence, their druggability, and their clinical use.
Competitor review
Trendsacross R&D efforts
Read the market
We summed up the work of key players developing new therapeutics and drew out trends across research and development efforts.
The Outcome
A clear view of where cytokines can deliver.
Prescouter helped the client establish whether cytokine cancer therapeutics were feasible, based on scientific and clinical evidence, and pinpoint the most promising cytokines on biological and technical grounds.
-
Feasibility
Which cytokines are most promising
A ranking built on biological and technical feasibility, backed by scientific and clinical evidence.
-
Entry
Where to enter the space
Refined entry options based on an analysis of competitive activity.
-
Next steps
New therapeutic and delivery ideas
Novel approaches that focused the client’s next steps in exploring acquisition targets.
Strong biology is only the start. Knowing which cytokines can be drugged, and who is already working on them, tells you where to place your bets.
Let’s Talk
Which therapies belong in your pipeline next?
Build your pipeline decisions on a clear view of the science, the competition, and the routes to market. Wherever you’re starting from, we’ll help you get there.
Or email [email protected]